Novo Nordisk (NVO) Unveils 10-Year Blueprint... Surpasses Lilly, but Stock Price Drops

▲ Novo Nordisk (NVO), Obesity Treatment/AI Generated Image

Danish pharmaceutical company Novo Nordisk (NVO) has unveiled its next-generation growth blueprint to lead the next 10 years. The company is aggressively expanding its new drug pipeline for next-generation obesity treatments while also improving its corporate structure through workforce reductions.

According to Benzinga on September 21 (local time), Novo Nordisk announced its mid-to-long-term global growth strategy at its '2026 Capital Markets Day' event. The company set a goal to launch more than five multi-blockbuster new drugs by 2030. Through the launch of new drugs, it plans to generate over 150 billion Danish Kroner (approximately 23.06 billion USD) in risk-adjusted revenue from its pipeline by 2035.

Organizational streamlining and cost reduction measures are also being implemented. Novo Nordisk reduced its workforce by approximately 13,000 employees, adjusting the total number of full-time employees to around 66,000. This restructuring saved over 10 billion Danish Kroner in operating costs. The funds secured will be reinvested in strengthening commercialization capabilities and advanced research and development (R&D) programs.

The new drug roadmap in preparation for the patent expiration of its existing flagship treatment, Semaglutide, has also been concretized. The company plans to introduce a new treatment to the market every year until 2030. Starting with CagriSema in 2027, Cagrilintide in 2028, and Zenagamtide in 2029 will be sequentially launched. The strategy is to diversify treatment areas to include cardiovascular, liver, and blood diseases to secure long-term revenue sources. Production capacity for oral GLP-1 obesity treatments will also be expanded tenfold to meet demand.

The results of a direct comparison Phase 3 clinical trial against competitor Eli Lilly and Co.'s (LLY) flagship treatment, Tirzepatide, were also fully disclosed. In the clinical trial 'REIMAGINE 5,' the CagriSema treatment group showed an average weight loss effect of 12.4%, surpassing the 9.1% weight loss in the Tirzepatide treatment group. The reduction rate of glycated hemoglobin (HbA1c) also recorded 1.71%, demonstrating non-inferiority compared to Tirzepatide's 1.67%. In another trial, 'REDEFINE 9,' a significant weight loss of 21.0% was observed, far exceeding the placebo group (2.0%).

However, the stock price showed weakness due to a combination of short-term performance slowdown and profit-taking sales. Novo Nordisk's Q2 revenue was 78.488 billion Danish Kroner, a 2% increase year-over-year but a 19% decrease quarter-over-quarter. On this day, Novo Nordisk's stock traded down 5.00% at $41.08 in pre-market trading on the New York Stock Exchange.

Amidst the patent expiration crisis, Novo Nordisk has made a decisive move with extensive new drug launches and workforce reductions. Based on clinical results that surpassed Eli Lilly, the pharmaceutical industry is keenly watching whether it can maintain its dominance in the global obesity treatment market.

[Article Summary]

-Novo Nordisk (NVO) announced a long-term roadmap to launch more than five multi-blockbuster new drugs by 2030.

-Reduced workforce by 13,000 employees, saving 10 billion Danish Kroner, and reinvesting in R&D and commercialization.

-Next-generation obesity treatment CagriSema demonstrated a higher weight loss effect of 12.4% in Phase 3 clinical trials compared to Eli Lilly's Tirzepatide.

*Disclaimer: This article is for investment reference only, and we are not responsible for any investment losses based on it. The content should be interpreted for informational purposes only.*